King's College London scientists develop tailored drug for triple-negative breast cancer using tumour-selective antibody.
Scientists at King's College London have developed a tailored drug to combat aggressive, triple-negative breast cancer, which typically has a lower survival rate and is resistant to chemotherapy and radiotherapy. By connecting a tumour-selective antibody with a cell-killing drug, researchers discovered a new method in cancer treatment. The findings, published in the journal Clinical Cancer Research, were made possible through data analysis of over 6,000 breast cancer samples.
May 21, 2024
5 Articles